The role of molecular markers in predicting response to therapy in patients with colorectal cancer

Veena Shankaran, Kari B. Wisinski, Mary F. Mulcahy, Al B. Benson

Research output: Contribution to journalReview article

20 Citations (Scopus)

Abstract

Advances in systemic therapy for colorectal cancer have dramatically improved prognosis. While disease stage has traditionally been the main determinant of disease course, several molecular characteristics of tumor specimens have recently been shown to have prognostic significance. Although to date no molecular characteristics have emerged as consistent predictors of response to therapy, retrospective studies have investigated the role of a variety of biomarkers, including microsatellite instability, loss of heterozygosity of 18q, type II transforming growth factor β receptor, thymidylate synthase, epidermal growth factor receptor, and Kirsten-ras (KRAS). This paper reviews the current literature, ongoing prospective studies evaluating the role of these markers, and novel techniques such as gene profiling, which may help to uncover the more complex molecular interactions that will predict response to chemotherapy in patients with colorectal cancer.

Original languageEnglish (US)
Pages (from-to)87-98
Number of pages12
JournalMolecular Diagnosis and Therapy
Volume12
Issue number2
DOIs
StatePublished - 2008

Fingerprint

Colorectal Neoplasms
Thymidylate Synthase
Microsatellite Instability
Growth Factor Receptors
Loss of Heterozygosity
Transforming Growth Factors
Epidermal Growth Factor Receptor
Retrospective Studies
Biomarkers
Prospective Studies
Drug Therapy
Therapeutics
Genes
Neoplasms

Keywords

  • Biomarkers
  • Colorectal cancer, treatment
  • Diagnostics

ASJC Scopus subject areas

  • Molecular Medicine
  • Genetics
  • Pharmacology

Cite this

@article{f2a75b7bfc98477499a4b4aa48b9b740,
title = "The role of molecular markers in predicting response to therapy in patients with colorectal cancer",
abstract = "Advances in systemic therapy for colorectal cancer have dramatically improved prognosis. While disease stage has traditionally been the main determinant of disease course, several molecular characteristics of tumor specimens have recently been shown to have prognostic significance. Although to date no molecular characteristics have emerged as consistent predictors of response to therapy, retrospective studies have investigated the role of a variety of biomarkers, including microsatellite instability, loss of heterozygosity of 18q, type II transforming growth factor β receptor, thymidylate synthase, epidermal growth factor receptor, and Kirsten-ras (KRAS). This paper reviews the current literature, ongoing prospective studies evaluating the role of these markers, and novel techniques such as gene profiling, which may help to uncover the more complex molecular interactions that will predict response to chemotherapy in patients with colorectal cancer.",
keywords = "Biomarkers, Colorectal cancer, treatment, Diagnostics",
author = "Veena Shankaran and Wisinski, {Kari B.} and Mulcahy, {Mary F.} and Benson, {Al B.}",
year = "2008",
doi = "10.1007/BF03256274",
language = "English (US)",
volume = "12",
pages = "87--98",
journal = "Molecular Diagnosis and Therapy",
issn = "1177-1062",
publisher = "Adis International Ltd",
number = "2",

}

The role of molecular markers in predicting response to therapy in patients with colorectal cancer. / Shankaran, Veena; Wisinski, Kari B.; Mulcahy, Mary F.; Benson, Al B.

In: Molecular Diagnosis and Therapy, Vol. 12, No. 2, 2008, p. 87-98.

Research output: Contribution to journalReview article

TY - JOUR

T1 - The role of molecular markers in predicting response to therapy in patients with colorectal cancer

AU - Shankaran, Veena

AU - Wisinski, Kari B.

AU - Mulcahy, Mary F.

AU - Benson, Al B.

PY - 2008

Y1 - 2008

N2 - Advances in systemic therapy for colorectal cancer have dramatically improved prognosis. While disease stage has traditionally been the main determinant of disease course, several molecular characteristics of tumor specimens have recently been shown to have prognostic significance. Although to date no molecular characteristics have emerged as consistent predictors of response to therapy, retrospective studies have investigated the role of a variety of biomarkers, including microsatellite instability, loss of heterozygosity of 18q, type II transforming growth factor β receptor, thymidylate synthase, epidermal growth factor receptor, and Kirsten-ras (KRAS). This paper reviews the current literature, ongoing prospective studies evaluating the role of these markers, and novel techniques such as gene profiling, which may help to uncover the more complex molecular interactions that will predict response to chemotherapy in patients with colorectal cancer.

AB - Advances in systemic therapy for colorectal cancer have dramatically improved prognosis. While disease stage has traditionally been the main determinant of disease course, several molecular characteristics of tumor specimens have recently been shown to have prognostic significance. Although to date no molecular characteristics have emerged as consistent predictors of response to therapy, retrospective studies have investigated the role of a variety of biomarkers, including microsatellite instability, loss of heterozygosity of 18q, type II transforming growth factor β receptor, thymidylate synthase, epidermal growth factor receptor, and Kirsten-ras (KRAS). This paper reviews the current literature, ongoing prospective studies evaluating the role of these markers, and novel techniques such as gene profiling, which may help to uncover the more complex molecular interactions that will predict response to chemotherapy in patients with colorectal cancer.

KW - Biomarkers

KW - Colorectal cancer, treatment

KW - Diagnostics

UR - http://www.scopus.com/inward/record.url?scp=42449115370&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42449115370&partnerID=8YFLogxK

U2 - 10.1007/BF03256274

DO - 10.1007/BF03256274

M3 - Review article

C2 - 18422373

AN - SCOPUS:42449115370

VL - 12

SP - 87

EP - 98

JO - Molecular Diagnosis and Therapy

JF - Molecular Diagnosis and Therapy

SN - 1177-1062

IS - 2

ER -